



NORTHAMPTONSHIRE PRESCRIBING ADVISORY GROUP
(Advising Medical, Pharmacy Practitioners and Non-Medical Prescribers
on prescribing across the county)

Summary of Recommendations from meeting on Wednesday 18th April 2018

- **Rosuvastatin**

NPAG agreed that the **generic preparations of rosuvastatin are classified as GREEN**, but for the **Crestor brand to be classified as DOUBLE RED (Prior Approval)**.

- **Tadalafil**

NPAG agreed for generic preparations of **tadalafil 10mg and 20mg to be classified as GREEN**, but for **Cialis brand to remain as DOUBLE RED (Prior Approval)**. The 2.5mg and 5mg preparations are licensed for daily use and are more expensive than the generic “when required” preparations. It was agreed the **2.5mg and 5mg are to remain DOUBLE RED (Prior Approval)**.

- **Riboflavin for migraine**

It can be purchased OTC so NPAG agreed **DOUBLE RED (IFR)**.

- **Pramipexole MR**

It was highlighted that for a small cohort of patients this may be a useful option prior to using apomorphine. It was confirmed that patients on m/r preparations could be switched to the branded generic Pipexus, and those on standard release could be switched to generic. **NPAG classified as AMBER 2.**

- **Enzalutamide**

Commissioned by NHS England for prostatic cancer, but as it is an oral preparation **NPAG classified as RED** to ensure it is not prescribed in primary care.

- **Duloxetine**

NICE Guidance advises that whilst duloxetine should not be routinely offered as a second-line treatment for women with stress urinary incontinence, it may be offered as second-line therapy if women prefer pharmacological to surgical treatment, or are not suitable for surgical treatment. Therefore the traffic light classification has been changed for stress urinary incontinence to **AMBER 2**. Duloxetine is not included in the Over Active Bladder guidance and remains as **DOUBLE RED** for this indication.

- **Free Style Libre (FSL)**

It has been agreed that Free Style Libre (FSL) should be available as a treatment option for the cohorts of patients recommended by NHS England’s Regional Medicines Optimisation Committees (RMOC) and who have undertaken appropriate training. It has been classified as AMBER 2 (specialist recommendation).

Receipt of a “Freestyle Libre advice letter” [link](#) from the diabetes specialists in secondary care, or the MDT, can be accepted by GP practices as confirmation that the patient has undertaken training and prescribing can be commenced.

- **Shared care**

- **Pentoxifylline and tocopherol for osteoradionecrosis of the jaw [link](#)**

- **Xultophy (insulin degludec and liraglutide)- for a defined cohort of patients [link](#)**

- **DMARDs for Rheumatology, Dermatology and Gastroenterology.** All existing drug-specific shared care documents on Pathfinder have been replaced by a single DMARD Shared Care Protocol agreed by both KGH and NGH, and has been updated to provide evidenced-based recommendations as per the latest BSR / BHPR guidelines. This new document also includes DMARDs used by KGH Neurology Department. For NGH shared care arrangement for azathioprine please refer to the separate document on Pathfinder.

Northamptonshire Prescribing Advisory Group Minutes and bullets can be viewed PathfinderRF via the following link:
<http://nwww.pathfinder-rf.northants.nhs.uk/nene>

Further information or clinical trial data may be obtained from the CCG Prescribing Advisers or Hospital Medicines Information Service.

Information in this bulletin is believed to be true and accurate. The NHS and their employees accept no liability for loss of any nature, to persons, organisations or institutions that may arise as a result of any errors or omissions.